Viveve Medical (VIVE) 10-Q 10 Nov 22 2022 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2022	Nov. 09, 2022
Document Information [Line Items]
Entity Central Index Key	0000879682
Entity Registrant Name	VIVEVE MEDICAL, INC.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2022
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2022
Document Transition Report	false
Entity File Number	1-11388
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	04-3153858
Entity Address, Address Line One	345 Inverness Drive South Building B, Suite 250
Entity Address, City or Town	Englewood
Entity Address, State or Province	CO
Entity Address, Postal Zip Code	80112
City Area Code	720
Local Phone Number	696-8100
Title of 12(b) Security	Common Stock
Trading Symbol	VIVE
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		10,723,857

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 5,907,000	$ 19,162,000
Accounts receivable, net of allowance for doubtful accounts of $15 and $66 as of September 30, 2022 and December 31, 2021, respectively	860,000	549,000
Inventory	1,615,000	1,472,000
Prepaid expenses and other current assets	1,222,000	1,055,000
Total current assets	9,604,000	22,238,000
Property and equipment, net	1,009,000	1,554,000
Investment in unconsolidated limited liability company	0	577,000
Other assets	1,541,000	1,544,000
Total assets	12,154,000	25,913,000
Current liabilities:
Accounts payable	1,108,000	1,480,000
Accrued liabilities	4,101,000	3,053,000
Note payable, current portion	5,628,000	0
Total current liabilities	10,837,000	4,533,000
Note payable, noncurrent portion	0	5,124,000
Other noncurrent liabilities	133,000	1,190,000
Total liabilities	10,970,000	10,847,000
Commitments and contingences (Note 9)
Stockholders’ equity:
Common stock, $0.0001 par value; 75,000,000 shares authorized as of September 30, 2022 and December 31, 2021; 10,698,857 and 10,619,846 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively	1,000	1,000
Additional paid-in capital	259,697,000	256,918,000
Accumulated deficit	(258,514,000)	(241,853,000)
Total stockholders’ equity	1,184,000	15,066,000
Total liabilities and stockholders’ equity	12,154,000	25,913,000
Series B Preferred Stock [Member]
Stockholders’ equity:
Convertible preferred stock	0	0
Series C Preferred Stock [Member]
Stockholders’ equity:
Convertible preferred stock	$ 0	$ 0

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Accounts receivable, allowance for doubtful accounts	$ 15	$ 66
Convertible preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	75,000,000	75,000,000
Common stock, shares issued (in shares)	10,698,857	10,619,846
Common stock, shares outstanding (in shares)	10,698,857	10,619,846
Series B Preferred Stock [Member]
Convertible preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Convertible preferred stock, shares issued (in shares)	44,413	40,504
Convertible preferred stock, shares outstanding (in shares)	44,413	40,504
Series C Preferred Stock [Member]
Convertible preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Convertible preferred stock, shares issued (in shares)	0	0
Convertible preferred stock, shares outstanding (in shares)	0	0

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenue	$ 1,684	$ 1,616	$ 5,120	$ 4,720
Cost of revenue	1,138	1,502	3,960	4,059
Gross profit	546	114	1,160	661
Operating expenses:
Research and development	1,800	2,695	5,861	6,804
Selling, general and administrative	3,408	2,911	10,454	9,423
Total operating expenses	5,208	5,606	16,315	16,227
Loss from operations	(4,662)	(5,492)	(15,155)	(15,566)
Gain on forgiveness of Paycheck Protection Program loan	0	0	0	1,358
Modification of warrants	0	0	0	(373)
Interest expense, net	(292)	(255)	(846)	(734)
Other expense, net	(22)	(78)	(83)	(196)
Net loss from consolidated companies	(4,976)	(5,825)	(16,084)	(15,511)
Impairment loss on investment in unconsolidated limited liability company	0	0	(455)	0
Loss from investment in unconsolidated limited liability company	0	(33)	(122)	(188)
Comprehensive and net loss	(4,976)	(5,858)	(16,661)	(15,699)
Series B convertible preferred stock dividends	(1,347)	(1,190)	(3,918)	(3,463)
Net loss attributable to common stockholders	$ (6,323)	$ (7,048)	$ (20,579)	$ (19,162)
Net loss per share of common stock:
Basic and diluted (in dollars per share)	$ (0.59)	$ (0.67)	$ (1.93)	$ (1.93)
Weighted average shares used in computing net loss per share of common stock:
Basic and diluted (in shares)	10,665,410	10,591,834	10,642,263	9,916,834

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	January 2021 Offering [Member] Preferred Stock [Member] Series B Preferred Stock [Member]	January 2021 Offering [Member] Preferred Stock [Member] Series C Preferred Stock [Member]	January 2021 Offering [Member] Common Stock [Member]	January 2021 Offering [Member] Additional Paid-in Capital [Member]	January 2021 Offering [Member] Retained Earnings [Member]	January 2021 Offering [Member]	Conversion of Series C Convertible Preferred Stock Into Common Stock [Member] Preferred Stock [Member] Series B Preferred Stock [Member]	Conversion of Series C Convertible Preferred Stock Into Common Stock [Member] Preferred Stock [Member] Series C Preferred Stock [Member]	Conversion of Series C Convertible Preferred Stock Into Common Stock [Member] Common Stock [Member]	Conversion of Series C Convertible Preferred Stock Into Common Stock [Member] Additional Paid-in Capital [Member]	Conversion of Series C Convertible Preferred Stock Into Common Stock [Member] Retained Earnings [Member]	Conversion of Series C Convertible Preferred Stock Into Common Stock [Member]	Preferred Stock [Member] Series B Preferred Stock [Member]	Preferred Stock [Member] Series C Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Series B Preferred Stock [Member]	Total
Balance (in shares) at Dec. 31, 2020													35,819	0	2,171,316
Balance at Dec. 31, 2020													$ 0	$ 0	$ 0	$ 226,800	$ (219,826)		$ 6,974
Dividend on Series B convertible preferred stock													$ 0	$ 0	$ 0	(1,119)	0		(1,119)
Dividend on Series B convertible preferred stock paid in PIK shares (in shares)													1,118	0	0
Dividend on Series B convertible preferred stock paid in PIK shares													$ 0	$ 0	$ 0	1,118	0		1,118
Stock-based compensation expense													0	0	0	810	0		810
Net loss													$ 0	$ 0	$ 0	0	(5,791)		(5,791)
Issuance of stock (in shares)	0	0	5,666,760
January 2021 Offering, net issuance costs	$ 0	$ 0	$ 1	$ 25,121	$ 0	$ 25,122
Conversion of convertible preferred stock into common stock (in shares)							0	0	2,450,880
Conversion of Series C convertible preferred stock into common stock							$ 0	$ 0	$ 0	$ 0	$ 0	$ 0
Issuance of common shares in connection with common warrant exercises (in shares)													0	0	52,760
Issuance of common shares in connection with common warrant exercises													$ 0	$ 0	$ 0	179	0		179
Modification of exercise price of warrants in connection with January 2021 Offering													0	0	0	287	0		287
Transaction costs in connection with Purchase Agreement with LPC													$ 0	$ 0	$ 0	(40)	0		(40)
Balance (in shares) at Mar. 31, 2021													36,937	0	10,341,716
Balance at Mar. 31, 2021													$ 0	$ 0	$ 1	253,156	(225,617)		27,540
Balance (in shares) at Dec. 31, 2020													35,819	0	2,171,316
Balance at Dec. 31, 2020													$ 0	$ 0	$ 0	226,800	(219,826)		6,974
Dividend on Series B convertible preferred stock paid in PIK shares (in shares)																		3,460
Net loss																			(15,699)
Balance (in shares) at Sep. 30, 2021													39,279	0	10,602,560
Balance at Sep. 30, 2021													$ 0	$ 0	$ 1	255,889	(235,525)		20,365
Balance (in shares) at Mar. 31, 2021													36,937	0	10,341,716
Balance at Mar. 31, 2021													$ 0	$ 0	$ 1	253,156	(225,617)		27,540
Dividend on Series B convertible preferred stock													$ 0	$ 0	$ 0	(1,154)	0		(1,154)
Dividend on Series B convertible preferred stock paid in PIK shares (in shares)													1,153	0	0
Dividend on Series B convertible preferred stock paid in PIK shares													$ 0	$ 0	$ 0	1,153	0		1,153
Stock-based compensation expense													0	0	0	867	0		867
Net loss													$ 0	$ 0	$ 0	0	(4,050)		(4,050)
Issuance of stock (in shares)													0		250,000
January 2021 Offering, net issuance costs													$ 0		$ 0	704	0		704
Transaction costs in connection with Purchase Agreement with LPC													0	$ 0	$ 0	(31)	0		(31)
Modification of exercise price of warrants in connection with First Amendment to Purchase Agreement with LPC													$ 0			86			86
Balance (in shares) at Jun. 30, 2021													38,090	0	10,591,716
Balance at Jun. 30, 2021													$ 0	$ 0	$ 1	254,781	(229,667)		25,115
Dividend on Series B convertible preferred stock													$ 0	$ 0	$ 0	(1,190)	0		(1,190)
Dividend on Series B convertible preferred stock paid in PIK shares (in shares)													1,189	0	0			1,189
Dividend on Series B convertible preferred stock paid in PIK shares													$ 0	$ 0	$ 0	1,189	0		1,189
Stock-based compensation expense													$ 0	$ 0	$ 0	1,088	0		1,088
Issuance of common shares from employee stock purchase plan (in shares)													0	0	10,844
Issuance of common shares from employee stock purchase plan													$ 0	$ 0	$ 0	21	0		21
Net loss													$ 0	$ 0	$ 0	0	(5,858)		(5,858)
Balance (in shares) at Sep. 30, 2021													39,279	0	10,602,560
Balance at Sep. 30, 2021													$ 0	$ 0	$ 1	255,889	(235,525)		20,365
Balance (in shares) at Dec. 31, 2021													40,504	0	10,619,846
Balance at Dec. 31, 2021													$ 0	$ 0	$ 1	256,918	(241,853)		15,066
Dividend on Series B convertible preferred stock													$ 0	$ 0	$ 0	(1,266)	0		(1,266)
Dividend on Series B convertible preferred stock paid in PIK shares (in shares)													1,263	0	0
Dividend on Series B convertible preferred stock paid in PIK shares													$ 0	$ 0	$ 0	1,263	0		1,263
Stock-based compensation expense													$ 0	$ 0	$ 0	960	0		960
Issuance of common shares from employee stock purchase plan (in shares)													0	0	20,691
Issuance of common shares from employee stock purchase plan													$ 0	$ 0	$ 0	19	0		19
Net loss													$ 0	$ 0	$ 0	0	(5,886)		(5,886)
Balance (in shares) at Mar. 31, 2022													41,767	0	10,640,537
Balance at Mar. 31, 2022													$ 0	$ 0	$ 1	257,894	(247,739)		10,156
Balance (in shares) at Dec. 31, 2021													40,504	0	10,619,846
Balance at Dec. 31, 2021													$ 0	$ 0	$ 1	256,918	(241,853)		15,066
Balance (in shares) at Jun. 30, 2022													43,069	0	10,665,042
Balance at Jun. 30, 2022													$ 0	$ 0	$ 1	258,813	(253,538)		5,276
Balance (in shares) at Dec. 31, 2021													40,504	0	10,619,846
Balance at Dec. 31, 2021													$ 0	$ 0	$ 1	256,918	(241,853)		15,066
Dividend on Series B convertible preferred stock paid in PIK shares (in shares)																		3,909
Net loss																			(16,661)
Balance (in shares) at Sep. 30, 2022													44,413	0	10,698,857
Balance at Sep. 30, 2022													$ 0	$ 0	$ 1	259,697	(258,514)		1,184
Balance (in shares) at Mar. 31, 2022													41,767	0	10,640,537
Balance at Mar. 31, 2022													$ 0	$ 0	$ 1	257,894	(247,739)		10,156
Dividend on Series B convertible preferred stock													$ 0	$ 0	$ 0	(1,305)	0		(1,305)
Dividend on Series B convertible preferred stock paid in PIK shares (in shares)													1,302	0	0
Dividend on Series B convertible preferred stock paid in PIK shares													$ 0	$ 0	$ 0	1,302	0		1,302
Stock-based compensation expense													$ 0	$ 0	$ 0	909	0		909
Issuance of common shares from employee stock purchase plan (in shares)													0	0	24,505
Issuance of common shares from employee stock purchase plan													$ 0	$ 0	$ 0	13	0		13
Net loss													$ 0	$ 0	$ 0	0	(5,799)		(5,799)
Balance (in shares) at Jun. 30, 2022													43,069	0	10,665,042
Balance at Jun. 30, 2022													$ 0	$ 0	$ 1	258,813	(253,538)		5,276
Dividend on Series B convertible preferred stock													$ 0	$ 0	$ 0	(1,347)			(1,347)
Dividend on Series B convertible preferred stock paid in PIK shares (in shares)													1,344	0	0			1,344
Dividend on Series B convertible preferred stock paid in PIK shares													$ 0	$ 0	$ 0	1,344			1,344
Stock-based compensation expense													$ 0	$ 0	$ 0	868			868
Issuance of common shares from employee stock purchase plan (in shares)													0	0	33,815
Issuance of common shares from employee stock purchase plan													$ 0	$ 0	$ 0	19			19
Net loss													$ 0	$ 0	$ 0	0	(4,976)		(4,976)
Balance (in shares) at Sep. 30, 2022													44,413	0	10,698,857
Balance at Sep. 30, 2022													$ 0	$ 0	$ 1	$ 259,697	$ (258,514)		$ 1,184

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended				9 Months Ended		12 Months Ended
	Sep. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Cash flows from operating activities:
Net loss	$ (4,976,000)	$ (5,886,000)	$ (5,858,000)	$ (5,791,000)	$ (16,661,000)	$ (15,699,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Provision for doubtful accounts					10,000	104,000
Depreciation and amortization					568,000	884,000
Stock-based compensation					2,737,000	2,765,000
Non-cash interest expense					504,000	446,000
Amortization of operating lease right-of-use assets and accretion of operating lease liabilities					(2,000)	15,000
Impairment loss on investment in unconsolidated limited liability company	0		0		455,000	0
Loss from investment in unconsolidated limited liability company	0		33,000		122,000	188,000
Loss on disposal of property and equipment					20,000	40,000
Modification of warrants	0		0		0	373,000
Gain on forgiveness of Paycheck Protection Program loan	0		0		0	(1,358,000)
Changes in assets and liabilities:
Accounts receivable					(321,000)	152,000
Inventory					115,000	1,423,000
Prepaid expenses and other current assets					(167,000)	213,000
Other assets					(161,000)	(3,000)
Accounts payable					(372,000)	411,000
Accrued liabilities					1,011,000	71,000
Other noncurrent liabilities					(863,000)	324,000
Net cash used in operating activities					(13,005,000)	(9,651,000)
Cash flows from investing activities:
Purchase of property and equipment					(301,000)	(162,000)
Net cash used in investing activities					(301,000)	(162,000)
Cash flows from financing activities:
Proceeds from January 2021 Offering, net of issuance costs					0	25,122,000
Proceeds from exercise of common warrants					0	179,000
Proceeds from purchase of common shares under Purchase Agreement with LPC					0	704,000
Proceeds from issuance of common shares from employee stock purchase plan					51,000	21,000
Net cash provided by financing activities					51,000	25,955,000
Net increase (decrease) in cash and cash equivalents					(13,255,000)	16,142,000
Cash and cash equivalents - beginning of period		$ 19,162,000		$ 6,523,000	19,162,000	6,523,000	$ 6,523,000
Cash and cash equivalents - end of period	$ 5,907,000		$ 22,665,000		5,907,000	22,665,000	$ 19,162,000
Supplemental disclosure:
Cash paid for interest					0	0
Cash paid for income taxes					0	0
Supplemental disclosure of cash flow information as of end of period:
Forgiveness of Paycheck Protection Program loan					0	1,358,000
Issuance of Series B convertible preferred stock in settlement of dividends					3,909,000	3,460,000
Issuance of note payable in settlement of accrued interest					502,000	443,000
Net transfer of equipment between inventory and property and equipment					(258,000)	(319,000)
Operating cash outflows from operating leases					209,000	195,000
Purchase Agreement with LPC [Member]
Cash flows from financing activities:
Transaction costs					$ 0	$ (71,000)

Note 1 - The Company and Basis

Note 1 - The Company and Basis of Presentation	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. The Company and Basis of Presentation Viveve Medical, Inc. (“Viveve Medical”, the “Company”, “we”, “our”, or “us”) designs, develops, manufactures and markets a platform medical technology, which we refer to as Cryogen-cooled Monopolar RadioFrequency Effective Shelf Registration Statement On July 2, 2021, 3, September 23, 2022, I.B.6. 3, 3 one third 12 September 30, 2022, not Reduction of Common Warrant Exercise Price On January 19, 2021, 2 2 2 2 no In February March 2021, January 2021 On May 4, 2021, 2 2 As of September 30, 2022, 2 2 2021 On January 19, 2021, “January 2021 The offering comprised of: ( 1 fifth 2 one one one fifth A total of 2,450,880 shares of Series C convertible preferred stock were issued in the January 2021 January 2021, Warrants to purchase a total of 8,117,640 shares of common stock were issued in the January 2021 February March 2021, January 2021 September 30, 2022, January 2021 Series C Convertible Preferred Stock In connection with the closing of the January 2021 With certain exceptions, as described in the Series C Certificate of Designation, the shares of Series C convertible preferred stock have no Each share of Series C convertible preferred stock is convertible at any time at the holder’s option into one share of common stock, which conversion ratio will be subject to adjustment for stock splits, stock dividends, distributions, subdivisions and combinations and other similar transactions as specified in the Series C Certificate of Designation. All Series C convertible preferred stock have been converted into common stock and there are no remaining shares outstanding. Elimination of Series C Convertible Preferred Stock On March 14, 2022, 2020 The Company previously entered into a purchase agreement on June 8, 2020, March 31, 2021 ( 11 As of September 30, 2022, The equity facility with LPC has a maturity date of January 9, 2023. Interim Unaudited Financial Information The accompanying unaudited condensed consolidated financial statements of Viveve Medical have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the instructions to Form 10 8 03 X. not The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Annual Report on Form 10 December 31, 2021, March 17, 2022. three nine September 30, 2022 not December 31, 2022 Liquidity and Management Plans The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. However, since inception, the Company has sustained significant operating losses and such losses are expected to continue for the foreseeable future. As of September 30, 2022, nine September 30, 2022. 2017 September 30, 2022 March 31, 2023. nine September 30, 2022 not November 30, 2023, one To fund further operations, the Company will need to raise additional capital. The Company may no not no Nasdaq Notice On May 31, 2022, 30 not $1.00 5550 2 5810 3 180 November 28, 2022, $1.00 ten 10 September 30, 2022, not $2.5 5550 1 $35 5550 2 $500,000 5550 3 may not may no may In the event that the Company’s common stock is delisted from Nasdaq, trading of its common stock could be conducted in the over-the-counter market or on an electronic bulletin board established for unlisted securities such as the Pink Sheets or the OTC Bulletin Board. In such event, it could become more difficult to dispose of, or obtain accurate price quotations for, the Company’s common stock, and there would likely also be a reduction in its coverage by security analysts and the news media, which could cause the price of the Company’s common stock to decline further. Also, it may not

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. Summary of Significant Accounting Policies Financial Statement Presentation The condensed consolidated financial statements include the accounts of the Company and our wholly-owned subsidiaries, Viveve, Inc. and Viveve BV. All significant intercompany accounts and transactions have been eliminated in consolidation. Use of Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue, and expenses and the related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not may Cash and Cash Equivalents The Company considers all highly liquid investments purchased with an original maturity of three may, Concentration of Credit Risk and Other Risks and Uncertainties To achieve profitable operations, the Company must successfully develop, manufacture, and market its products. There can be no Most of the Company’s products to date require clearance or approvals from the U.S. Food and Drug Administration or other international regulatory agencies prior to commencing commercial sales. There can be no The Company is subject to risks common to companies in the medical device industry including, but not The Company designs, develops, manufactures and markets a medical device that it refers to as the Viveve System, which is intended for the non-invasive treatment of vaginal introital laxity, for improved sexual function, for vaginal rejuvenation, for use in general surgical procedures for electrocoagulation and hemostasis, and stress urinary incontinence, depending on the relevant country-specific clearance or approval. The Viveve System consists of three four five third In the United States, the Company sells its products primarily through a direct sales force to health care practitioners. Outside the United States, the Company sells through an extensive network of distribution partners. During the three September 30, 2022, nine September 30, 2022, three nine September 30, 2021, As of September 30, 2022, December 31, 2021, Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable are recorded at the invoiced amount and are not six may six not During the three nine September 30, 2022, three nine September 30, 2021, Revenue from Contracts with Customers Revenue consists primarily of the sale of the Viveve System, single-use treatment tips and ancillary consumables. The Company applies the following five 1 2 3 4 5 Rental revenue is generated through the lease of the Viveve System. The Company’s operating leases for the Viveve System generally have a rental period of 6 to 12 months and can be extended or terminated by the customer after that time or the Viveve System could be purchased by the customer. Rental revenue on those operating leases is recognized on a straight-line basis over the terms of the underlying leases. For the three nine September 30, 2022, three nine September 30, 2021, September 30, 2022 December 31, 2021, three nine September 30, 2022, December 31, 2021. three nine September 30, 2021, December 31, 2020. In connection with the lease of the Viveve System, the Company offers single-use treatment tips and ancillary consumables that are considered non-lease components. In the contracts with lease and non-lease components, the Company follows the relevant guidance in Accounting Standards Codification 606, Sales of our products are subject to regulatory requirements that vary from country to country. The Company has regulatory clearance for differing indications, or can sell its products without a clearance, in many countries throughout the world, including countries within the following regions: North America, Asia Pacific, Europe, the Middle East and Latin America. In the United States, we market and sell primarily through a direct sales force. Outside of the United States, we market and sell primarily through distribution partners. The Company does not Customer Advance Payments From time to time, customers will pay for a portion of the products ordered in advance. Upon receipt of such payments, the Company records the customer advance payment as a component of accrued liabilities on the condensed consolidated balance sheets. The Company will remove the customer advance payment from accrued liabilities when revenue is recognized upon shipment of the products. Contract Assets and Liabilities The Company continually evaluates whether the revenue generating activities and advanced payment arrangements with customers result in the recognition of contract assets or liabilities. No such assets existed as of September 30, 2022, December 31, 2021. not September 30, 2022 December 31, 2021, Significant Financing Component The Company applies the practical expedient to not not one three nine September 30, 2022, not Contract Costs The Company expects that commissions paid to obtain subscriptions are recoverable and has therefore capitalized them as a contract cost in the amount of $60,000 and $84,000 as of September 30, 2022 December 31, 2021, three September 30, 2022 2021, nine September 30, 2022 2021, no Shipping and Handling Shipping costs billed to customers are recorded as revenue. Shipping and handling expense related to costs incurred to deliver product are recognized within cost of revenue. The Company accounts for shipping and handling activities that occur after control has transferred as a fulfillment cost as opposed to a separate performance obligation, and the costs of shipping and handling are recognized concurrently with the related revenue. Revenue by Geographic Area Management has determined that the sales by geography is a key indicator for understanding the Company’s financial performance because of the different sales and business models that are required in the various regions of the world (including regulatory, selling channels, pricing, customers and marketing efforts). The following table presents the revenue from unaffiliated customers disaggregated by geographic area for the three nine September 30, 2022 2021 Three Months Ended Nine Months Ended September 30, September 30, 2022 2021 2022 2021 North America $ 973 $ 939 $ 2,844 $ 2,857 Asia Pacific 708 677 2,270 1,855 Europe and Middle East 3 - 6 8 Total $ 1,684 $ 1,616 $ 5,120 $ 4,720 The Company determines geographic location of its revenue based upon the destination of the shipments of its products. Investments in Unconsolidated Affiliates The Company uses the equity method to account for its investments in entities that it does not 1 2 3 three not The Company assesses the potential impairment of the equity method investments when indicators such as a history of operating losses, a negative earnings and cash flow outlook, and the financial condition and prospects for the investee’s business segment might indicate a loss in value. The carrying value of the investments is reviewed annually for changes in circumstances or the occurrence of events that suggest the investment may not three June 30, 2022, 4 2022 2021. Product Warranty The Company’s products sold to customers are generally subject to warranties between one three not Accounting for Stock-Based Compensation Share-based compensation cost is measured at grant date, based on the fair value of the award, and is recognized as expense over the employee’s service period. The Company recognizes compensation expense on a straight-line basis over the requisite service period of the award. The Company determined that the Black-Scholes option pricing model is the most appropriate method for determining the estimated fair value for stock options and purchase rights under the employee stock purchase plan. The Black-Scholes option pricing model requires the use of highly subjective and complex assumptions which determine the fair value of share-based awards, including the option’s expected term and the price volatility of the underlying stock. Equity instruments issued to nonemployees are recorded in the same manner as similar instruments issued to employees. Comprehensive Loss Comprehensive loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive loss may three nine September 30, 2022 2021, Net Loss per Share The Company’s basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. The diluted net loss per share is computed by giving effect to all potentially dilutive common stock equivalents outstanding during the period. For purposes of this calculation, stock options and warrants to purchase common stock and restricted common stock awards are considered common stock equivalents. For periods in which the Company has reported net losses, diluted net loss per share is the same as basic net loss per share since dilutive common shares are not The following securities were excluded from the calculation of net loss per share because the inclusion would be anti-dilutive: Nine Months Ended September 30, 2022 2021 Convertible preferred stock: Series B convertible preferred stock (a) 2,902,810 2,567,255 Series C convertible preferred stockStockholders’ (b) - - Warrants to purchase common stock 9,793,599 9,793,599 Stock options to purchase common stock 4,105,706 3,195,742 Deferred restricted common stock units 668,000 679,000 Deferred restricted common stock awards 226 228 (a) As of September 30, 2022 2021, 1 not (b) Each share of Series C convertible preferred stock was convertible at any time at the holder’s option into one share of common stock. All Series C convertible preferred stock had been converted into common stock and there were no remaining shares outstanding. In March 2022, Recently Issued Accounting Standards In June 2016, 2016 13, 326 2016 13” not 2016 13 December 15, 2022 We have reviewed other recent accounting pronouncements and concluded they are either not no

Note 3 - Fair Value Measurement

Note 3 - Fair Value Measurements	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Fair Value Disclosures [Text Block]	3. Fair Value Measurements The Company recognizes and discloses the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 3 Level 1 Inputs used to measure fair value are unadjusted quoted prices that are available in active markets for the identical assets or liabilities as of the reporting date. Therefore, determining fair value for Level 1 not not Level 2 Pricing is provided by third not Level 3 Inputs used to measure fair value are unobservable inputs that are supported by little or no 3 Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. There were no September 30, 2022 December 31, 2021. The carrying amounts of the Company’s financial assets and liabilities, including cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities as of September 30, 2022 December 31, 2021 There were no

Note 4 - Investment in Unconsol

Note 4 - Investment in Unconsolidated Limited Liability Company	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Equity Method Investments and Joint Ventures Disclosure [Text Block]	4. Investment in Unconsolidated Limited Liability Company On August 8, 2017, In connection with the Distributorship Agreement, the Company also entered into a Membership Unit Subscription Agreement with ICM and the associated limited liability company operating agreement of ICM, pursuant to which the Company invested $2,500,000 in, and acquired membership units of, ICM. This investment has been recorded in investment in an unconsolidated limited liability company on the condensed consolidated balance sheets. The Company used the equity method to account for the investment in ICM because the Company does not September 30, 2022, three three September 30, 2022 2021, nine September 30, 2022 2021, second 2022, not second third 2022. During the three June 30, 2022, June 30, 2022. During the three September 30, 2022 2021, nine September 30, 2022 2021, September 30, 2022, three September 30, 2022 2021, $0 nine September 30, 2022 2021, September 30, 2022 December 31, 2021. In February 2019,

Note 5 - Accrued Liabilities

Note 5 - Accrued Liabilities	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	5. Accrued Liabilities Accrued liabilities consisted of the following as of September 30, 2022 December 31, 2021 ( September 30, December 31, 2022 2021 Accrued interest $ 1,229 $ - Accrued bonuses 906 1,209 Accrued payroll and other related expenses 557 495 Deferred revenue - subscription rental program 412 448 Accrued professional fees 332 120 Current operating lease liabilities 253 225 Accrued clinical trial costs 248 337 Other accruals 164 219 Total accrued liabilities $ 4,101 $ 3,053

Note 6 - Note Payable

Note 6 - Note Payable	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Debt Disclosure [Text Block]	6. Note Payable On May 22, 2017, December 12, 2017 November 29, 2018 ( “2017 December 29, 2017, In connection with the 2017 two 11 Under the 2017 November 12, 2019 six four 2017 may, As collateral for its obligations under the 2017 The terms of the 2017 2017 On November 12, 2019, 2017 No. 3” 11 one The Amendment No. 3 2017 ● repayment provisions were amended such that repayment is permitted only with, or after, the redemption in full of the Series B convertible preferred stock issued to CRG; ● the interest only payment period and the period during which the Company may 23rd first no 2017 ● modified certain of the covenants, including (i) to permit issuance of the Series B convertible preferred stock and any preferred stock issued in the equity financing and the exercise and performance by the Company of its rights and obligations in connection with such CRG preferred stock and any preferred stock issued in the equity financing, (ii) eliminate the Company’s ability to enter into permitted acquisitions, (iii) further restrict the incurrence of additional indebtedness and removal of the equity cure right, and (iv) eliminate the minimum revenue requirement; and ● the back-end facility fee on the aggregate remaining principal balance on the term loan shall be increased from 5% to 25%. Pursuant to the amendment, the Company paid interest in-kind of $175,000 and $502,000 during the three nine September 30, 2022, three nine September 30, 2021, As of September 30, 2022, The term loan has a maturity date of March 31, 2023. As of September 30, 2022, December 31, 2021, As of September 30, 2022, Year Ending December 31, 2022 (remaining three months) $ - 2023 5,992 Total payments 5,992 Less: Amount representing interest (362 ) Present value of obligations 5,630 Less: Unamortized debt discount (2 ) Note payable, current portion $ 5,628

Note 7 - Paycheck Protection Pr

Note 7 - Paycheck Protection Program Loan	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Long-Term Debt [Text Block]	7. Paycheck Protection Program Loan The Paycheck Protection Program (“PPP”) was established under the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) and is administered by the U.S. Small Business Administration. On April 24, 2020, 1.00% two On May 25, 2021, May 21, 2021,

Note 8 - Leases

Note 8 - Leases	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	8. Leases Lessee: The following information pertains to those operating lease agreements where the Company is the lessee. In February 2017, June 2017 May 2021. March 2021, March 31, 2024. June 2021. In October 2020, December 2020 December 2023. Operating lease rentals are expensed on a straight-line basis over the life of the lease beginning on the date the Company takes possession of the property. At lease inception, the Company determines the lease term by assuming the exercise of those renewal options that are reasonably assured. The lease term is used to determine whether a lease is financing or operating and is used to calculate straight-line rent expense. Additionally, the depreciable life of leasehold improvements is limited by the expected lease term. Leases with an initial term of 12 not The following table reflects the Company’s lease assets and lease liabilities as of September 30, 2022 December 31, 2021 ( September 30, December 31, 2022 2021 Assets: Operating lease right-of-use assets $ 370 $ 534 Liabilities: Current operating lease liabilities $ 253 $ 225 Noncurrent operating lease liabilities 133 327 $ 386 $ 552 The operating lease right-of-use assets are included in other assets on the condensed consolidated balance sheets. The operating lease liabilities are included in accrued liabilities and other noncurrent liabilities on the condensed consolidated balance sheets. The operating lease expense for the three September 30, 2022 2021 nine September 30, 2022 2021 As of September 30, 2022, Year Ending December 31, 2022 (remaining three months) $ 71 2023 287 2024 67 Total lease payments 425 Less: Amount representing interest (39 ) Present value of lease liabilities $ 386 The weighted average remaining lease term was approximately 18 September 30, 2022. three September 30, 2022 Lessor: The following information pertains to those operating lease agreements where the Company is the lessor. As of September 30, 2022, Year Ending December 31, 2022 (remaining three months) $ 202 2023 210 Total $ 412 As of September 30, 2022, three nine September 30, 2022 three nine September 30, 2021,

Note 9 - Commitments and Contin

Note 9 - Commitments and Contingencies	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	9. Commitments and Contingencies Indemnification Agreements The Company enters into standard indemnification arrangements in the ordinary course of business. Pursuant to these arrangements, the Company indemnifies, holds harmless and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with performance of services within the scope of the agreement, breach of the agreement by the Company, or noncompliance of regulations or laws by the Company, in all cases provided the indemnified party has not not not Loss Contingencies The Company is or has been subject to proceedings, lawsuits and other claims arising in the ordinary course of business. The Company evaluates contingent liabilities, including threatened or pending litigation, for potential losses. If the potential loss from any claim or legal proceeding is considered probable and the amount can be estimated, the Company accrues a liability for the estimated loss. Because of uncertainties related to these matters, accruals are based upon the best information available. For potential losses for which there is a reasonable possibility (meaning the likelihood is more than remote but less than probable) that a loss exists, the Company will disclose an estimate of the potential loss or range of such potential loss or include a statement that an estimate of the potential loss cannot be made. As additional information becomes available, the Company reassesses the potential liability related to pending claims and litigation and may Management does not

Note 10 - Preferred Stock

Note 10 - Preferred Stock	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Preferred Stock [Text Block]	10. Preferred Stock Series B Convertible Preferred Stock As previously reported (see Note 6 In connection with the CRG debt conversion, on November 26, 2019, three September 30, 2022, three September 30, 2021, nine September 30, 2022, nine September 30, 2021, September 30, 2022. As of September 30, 2022 December 31, 2021, 1 not The shares of Series B convertible preferred stock have no The Series B convertible preferred stock also provides that for so long as any shares are outstanding, the consent of the holders of the Series B convertible preferred stockholders would be required to amend the Company’s organizational documents, approve any merger, sale of assets, or other major corporate transaction, or incur additional indebtedness, among other items. Series C Convertible Preferred Stock In connection with the closing of the public offering, on January 19, 2021, With certain exceptions, as described in the Series C Certificate of Designation, the shares of Series C convertible preferred stock have no Each share of Series C convertible preferred stock is convertible at any time at the holder’s option into one A total of 2,450,880 shares of Series C convertible preferred stock were issued in the January 2021 January 2021, On March 14, 2022,

Note 11 - Common Stock

Note 11 - Common Stock	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	11. Common Stock 2020 The Company previously entered into the Purchase Agreement with LPC, which provided that the Company had the right, in its sole discretion, to sell to LPC, and LPC has committed to purchase from us up to $10,000,000 of our common stock, subject to certain limitations, from time to time over a 30-month term of the Purchase Agreement. The Purchase Agreement limited the Company’s sale of shares of common stock to LPC to 301,762 shares of common stock, representing 19.99% of the shares of the common stock outstanding on the date of the Purchase Agreement unless (i) shareholder approval was obtained to issue more than such amount or (ii) the average price of all applicable sales of common stock to LPC under the Purchase Agreement equaled or exceeded $6.46 per share. On June 9, 2020, On March 31, 2021, first five On May 4, 2021, On June 23, 2021, As of September 30, 2022, The equity facility with LPC has a maturity date of January 9, 2023. 2021 On January 19, 2021, January 2021 The offering comprised of: ( 1 fifth 2 fifth A total of 2,450,880 shares of Series C convertible preferred stock were issued in the January 2021 January 2021, Warrants to purchase a total of 8,117,640 shares of common stock were issued in the January 2021 February March 2021, January 2021 September 30, 2022, January 2021 Restricted Common Shares There were no restricted common shares issued during the three nine September 30, 2022 2021. Warrants for Common Stock As of September 30, 2022, Number of Shares Outstanding Exercisable Expiration Exercise Under Issuance Date for Date Price Warrants February 2015 Common Shares February 17, 2025 $ 4,000.00 79 March 2015 Common Shares March 26, 2025 $ 2,720.00 2 May 2015 Common Shares May 12, 2025 $ 4,240.00 37 December 2015 Common Shares December 16, 2025 $ 5,600.00 31 April 2016 Common Shares April 1, 2026 $ 6,080.00 25 June 2016 Common Shares June 20, 2026 $ 4,980.00 101 May 2017 Common Shares May 25, 2027 $ 9,500.00 223 November 2019 Common Shares November 26, 2024 $ 18.36 989,379 November 2019 Common Shares November 26, 2024 $ 2.82 285,632 April 2020 Common Shares April 21, 2025 $ 2.82 413,210 January 2021 Common Shares January 19, 2026 $ 3.40 8,104,880 9,793,599 In connection with the 2017 ten three nine September 30, 2022, three nine September 30, 2021, September 30, 2022, In connection with the January 2021 fifth As a result of the closing of the January 2021 2 2 2 2 no 2 2 Immediately Immediately before After Series B Warrants Modification Modification Exercise price $ 6.10 $ 3.40 Common stock price $ 3.19 $ 3.19 Expected term (in years) 3.9 3.9 Average volatility 90 % 90 % Risk-free interest rate 0.33 % 0.33 % Dividend yield 0 % 0 % Immediately Immediately before After Series A-2 and B-2 Warrants Modification Modification Exercise price $ 6.37 $ 3.40 Common stock price $ 3.19 $ 3.19 Expected term (in years) 4.3 4.3 Average volatility 90 % 90 % Risk-free interest rate 0.33 % 0.33 % Dividend yield 0 % 0 % On May 4, 2021, 2 2 no 2 2 Immediately Immediately before After Series B, A-2 and B-2 Warrants Modification Modification Exercise price $ 3.40 $ 2.82 Common stock price $ 3.01 $ 3.01 Expected term (in years) 3.6 3.6 Average volatility 80 % 80 % Risk-free interest rate 0.58 % 0.58 % Dividend yield 0 % 0 % The incremental fair value of the Series B, A- 2 2 In February 2021, January 2021 In March 2021, January 2021 No shares issuable pursuant to warrants have been cancelled during the three nine September 30, 2022 2021. No shares issuable pursuant to warrants expired during the three nine September 30, 2022. three September 30, 2021. nine September 30, 2021. As of September 30, 2022, As of September 30, 2022, 2 2 As of September 30, 2022, January 2021

Note 12 - Summary of Stock Opti

Note 12 - Summary of Stock Options	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Share-Based Payment Arrangement [Text Block]	12. Summary of Stock Options Stock Option Plans The Company has issued equity awards in the form of stock options (both incentive stock options and non-qualified stock options) and deferred restricted stock awards or units, from two 2006 “2006 2013 “2013 As of September 30, 2022, 2006 Effective January 1, 2022, 2013 2013 As of September 30, 2022, 2013 Activity under the 2006 2013 Nine Months Ended September 30, 2022 Weighted Weighted Average Number Average Remaining Aggregate of Exercise Contractual Intrinsic Shares Price Term (years) Value Options outstanding, January 1, 2022 3,173,103 $ 7.51 9.0 $ - Options granted 959,000 $ 1.25 Options exercised - Options canceled (26,397 ) $ 8.02 Options outstanding, September 30, 2022 4,105,706 $ 6.05 8.5 $ 80 Vested and exercisable and expected to vest, September 30, 2022 3,895,519 $ 6.24 8.5 $ 71 Vested and exercisable, September 30, 2022 1,521,946 $ 11.45 8.1 $ - The aggregate intrinsic value reflects the difference between the exercise price of the underlying stock options and the Company’s closing share price as of September 30, 2022. The options outstanding and exercisable as of September 30, 2022 Weighted Number Weighted Average Number Weighted Outstanding Average Remaining Exercisable Average Range of as of Exercise Contractual as of Exercise Exercise Prices September 30, 2022 Price Term (Years) September 30, 2022 Price $0.66 - $1.26 953,167 $ 1.25 9.3 157,712 $ 1.26 $2.28 - $2.96 2,196,021 $ 2.73 8.7 688,362 $ 2.73 $3.06 - $3.40 10,000 $ 3.20 8.5 3,771 $ 3.20 $4.45 - $4.80 11,900 $ 4.72 8.2 5,319 $ 4.71 $5.10 - $5.40 88,000 $ 5.28 8.0 63,250 $ 5.34 $6.90 - $6.90 5,400 $ 6.90 7.5 3,376 $ 6.90 $8.60 - $8.91 822,332 $ 8.69 7.1 583,220 $ 8.69 $10.90 - $13.60 15,500 $ 12.64 7.4 13,553 $ 12.89 $380.00 - $9,920.00 3,386 $ 2,869.31 5.5 3,383 $ 2,870.91 Total: 4,105,706 $ 6.05 8.5 1,521,946 $ 11.45 Deferred Restricted Stock Units As of September 30, 2022, 2013 During the three nine September 30, 2022, In January 2021, 2013 second During the three nine September 30, 2022, three nine September 30, 2021, 2013 Deferred Restricted Stock Awards As of September 30, 2022, 2013 During the three nine September 30, 2022 2021, During the three nine September 30, 2022, three nine September 30, 2021, 2013 2017 In September 2020, 2017 “2017 twelfth September 30, 2020. In June 2021, 2017 Following the Company’s annual stockholders’ meeting, the board of directors approved to reactivate the ESPP effective with the offering period beginning on July 1, 2021. The activity of the Company’s 2017 three nine September 30, 2022 ● The fifteenth 2017 January 1, 2022, March 31, 2022, March 31, 2022 ● The sixteenth 2017 April 1, 2022, June 30, 2022, June 30, 2022 ● The seventeenth 2017 July 1, 2022, September 30, 2022, September 30, 2022, The activity of the Company’s 2017 three nine September 30, 2021 ● The thirteenth 2017 July 1, 2021, September 30, 2021, September 30, 2020 The Company estimated the fair value of purchase rights under the 2017 As of September 30, 2022, 2017 November 2022, 2017 December 31, 2022 April 1, 2022. Stock-Based Compensation During the three September 30, 2022, three September 30, 2021, nine September 30, 2022, nine September 30, 2021, The Company estimated the fair value of stock options using the Black-Scholes option pricing model. The fair value of stock options is being amortized on a straight-line basis over the requisite service period of the awards. The fair value of stock options granted was estimated using the following weighted average assumptions: Three Months Ended Nine Months Ended September 30, September 30, 2022 2021 2022 2021 Expected term (in years) 6 5 6 6 Average volatility 89 % 84 % 88 % 76 % Risk-free interest rate 2.69 % 0.81 % 1.46 % 0.97 % Dividend yield 0 % 0 % 0 % 0 % Option-pricing models require the input of various subjective assumptions, including the option’s expected life and the price volatility of the underlying stock. The expected stock price volatility is based on analysis of the Company’s stock price history over a period commensurate with the expected term of the options, trading volume of comparable companies’ stock, look-back volatilities and the Company specific events that affected volatility in a prior period. The expected term of stock options represents the weighted average period the stock options are expected to remain outstanding and is based on the history of exercises and cancellations on all past option grants made by the Company, the contractual term, the vesting period and the expected remaining term of the outstanding options. The risk-free interest rate is based on the U.S. Treasury interest rates whose term is consistent with the expected life of the stock options. No dividend yield is included as the Company has not not The following table shows stock-based compensation expense for options, RSUs and ESPP shares included in the condensed consolidated statements of operations for the three nine September 30 2022 2021 Three Months Ended Nine Months Ended September 30, September 30, 2022 2021 2022 2021 Cost of revenue $ 64 $ 76 $ 193 $ 191 Research and development 118 131 361 330 Selling, general and administrative 686 881 2,183 2,244 Total $ 868 $ 1,088 $ 2,737 $ 2,765 As of September 30, 2022, The fair value of the RSUs is determined on the grant date based on the fair value of the Company’s common stock. The fair value of the RSUs is recognized as expense ratably over the vesting period of two As of September 30, 2022, 0.3years.

Note 13 - Income Taxes

Note 13 - Income Taxes	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Income Tax Disclosure [Text Block]	13. Income Taxes No provision for income taxes has been recorded due to the net operating losses incurred from inception to date, for which no benefit has been recorded. For interim periods, the Company estimates its annual effective income tax rate and applies the estimated rate to the year-to-date income or loss before income taxes. The Company also computes the tax provision or benefit related to items reported separately and recognizes the items net of their related tax effect in the interim periods in which they occur. The Company also recognizes the effect of changes in enacted tax laws or rates in the interim periods in which the changes occur. The Company’s effective tax rate is 0% for the three nine September 30, 2022 2021. 2022

Note 14 - Related Party Transac

Note 14 - Related Party Transactions	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	14. Related Party Transactions In June 2006, October 4, 2007. first September 2019. no three September 30, 2022 2021, nine September 30, 2022 2021, September 30, 2022 December 31, 2021

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Financial Statement Presentation The condensed consolidated financial statements include the accounts of the Company and our wholly-owned subsidiaries, Viveve, Inc. and Viveve BV. All significant intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue, and expenses and the related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not may
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents The Company considers all highly liquid investments purchased with an original maturity of three may,
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk and Other Risks and Uncertainties To achieve profitable operations, the Company must successfully develop, manufacture, and market its products. There can be no Most of the Company’s products to date require clearance or approvals from the U.S. Food and Drug Administration or other international regulatory agencies prior to commencing commercial sales. There can be no The Company is subject to risks common to companies in the medical device industry including, but not The Company designs, develops, manufactures and markets a medical device that it refers to as the Viveve System, which is intended for the non-invasive treatment of vaginal introital laxity, for improved sexual function, for vaginal rejuvenation, for use in general surgical procedures for electrocoagulation and hemostasis, and stress urinary incontinence, depending on the relevant country-specific clearance or approval. The Viveve System consists of three four five third In the United States, the Company sells its products primarily through a direct sales force to health care practitioners. Outside the United States, the Company sells through an extensive network of distribution partners. During the three September 30, 2022, nine September 30, 2022, three nine September 30, 2021, As of September 30, 2022, December 31, 2021,
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]	Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable are recorded at the invoiced amount and are not six may six not During the three nine September 30, 2022, three nine September 30, 2021,
Equity Method Investments [Policy Text Block]	Revenue from Contracts with Customers Revenue consists primarily of the sale of the Viveve System, single-use treatment tips and ancillary consumables. The Company applies the following five 1 2 3 4 5 Rental revenue is generated through the lease of the Viveve System. The Company’s operating leases for the Viveve System generally have a rental period of 6 to 12 months and can be extended or terminated by the customer after that time or the Viveve System could be purchased by the customer. Rental revenue on those operating leases is recognized on a straight-line basis over the terms of the underlying leases. For the three nine September 30, 2022, three nine September 30, 2021, September 30, 2022 December 31, 2021, three nine September 30, 2022, December 31, 2021. three nine September 30, 2021, December 31, 2020. In connection with the lease of the Viveve System, the Company offers single-use treatment tips and ancillary consumables that are considered non-lease components. In the contracts with lease and non-lease components, the Company follows the relevant guidance in Accounting Standards Codification 606, Sales of our products are subject to regulatory requirements that vary from country to country. The Company has regulatory clearance for differing indications, or can sell its products without a clearance, in many countries throughout the world, including countries within the following regions: North America, Asia Pacific, Europe, the Middle East and Latin America. In the United States, we market and sell primarily through a direct sales force. Outside of the United States, we market and sell primarily through distribution partners. The Company does not Customer Advance Payments From time to time, customers will pay for a portion of the products ordered in advance. Upon receipt of such payments, the Company records the customer advance payment as a component of accrued liabilities on the condensed consolidated balance sheets. The Company will remove the customer advance payment from accrued liabilities when revenue is recognized upon shipment of the products. Contract Assets and Liabilities The Company continually evaluates whether the revenue generating activities and advanced payment arrangements with customers result in the recognition of contract assets or liabilities. No such assets existed as of September 30, 2022, December 31, 2021. not September 30, 2022 December 31, 2021, Significant Financing Component The Company applies the practical expedient to not not one three nine September 30, 2022, not Contract Costs The Company expects that commissions paid to obtain subscriptions are recoverable and has therefore capitalized them as a contract cost in the amount of $60,000 and $84,000 as of September 30, 2022 December 31, 2021, three September 30, 2022 2021, nine September 30, 2022 2021, no Shipping and Handling Shipping costs billed to customers are recorded as revenue. Shipping and handling expense related to costs incurred to deliver product are recognized within cost of revenue. The Company accounts for shipping and handling activities that occur after control has transferred as a fulfillment cost as opposed to a separate performance obligation, and the costs of shipping and handling are recognized concurrently with the related revenue. Revenue by Geographic Area Management has determined that the sales by geography is a key indicator for understanding the Company’s financial performance because of the different sales and business models that are required in the various regions of the world (including regulatory, selling channels, pricing, customers and marketing efforts). The following table presents the revenue from unaffiliated customers disaggregated by geographic area for the three nine September 30, 2022 2021 Three Months Ended Nine Months Ended September 30, September 30, 2022 2021 2022 2021 North America $ 973 $ 939 $ 2,844 $ 2,857 Asia Pacific 708 677 2,270 1,855 Europe and Middle East 3 - 6 8 Total $ 1,684 $ 1,616 $ 5,120 $ 4,720 The Company determines geographic location of its revenue based upon the destination of the shipments of its products.
Standard Product Warranty, Policy [Policy Text Block]	Product Warranty The Company’s products sold to customers are generally subject to warranties between one three not
Share-Based Payment Arrangement [Policy Text Block]	Accounting for Stock-Based Compensation Share-based compensation cost is measured at grant date, based on the fair value of the award, and is recognized as expense over the employee’s service period. The Company recognizes compensation expense on a straight-line basis over the requisite service period of the award. The Company determined that the Black-Scholes option pricing model is the most appropriate method for determining the estimated fair value for stock options and purchase rights under the employee stock purchase plan. The Black-Scholes option pricing model requires the use of highly subjective and complex assumptions which determine the fair value of share-based awards, including the option’s expected term and the price volatility of the underlying stock. Equity instruments issued to nonemployees are recorded in the same manner as similar instruments issued to employees.
Comprehensive Income, Policy [Policy Text Block]	Comprehensive Loss Comprehensive loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive loss may three nine September 30, 2022 2021,
Earnings Per Share, Policy [Policy Text Block]	Net Loss per Share The Company’s basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. The diluted net loss per share is computed by giving effect to all potentially dilutive common stock equivalents outstanding during the period. For purposes of this calculation, stock options and warrants to purchase common stock and restricted common stock awards are considered common stock equivalents. For periods in which the Company has reported net losses, diluted net loss per share is the same as basic net loss per share since dilutive common shares are not The following securities were excluded from the calculation of net loss per share because the inclusion would be anti-dilutive: Nine Months Ended September 30, 2022 2021 Convertible preferred stock: Series B convertible preferred stock (a) 2,902,810 2,567,255 Series C convertible preferred stockStockholders’ (b) - - Warrants to purchase common stock 9,793,599 9,793,599 Stock options to purchase common stock 4,105,706 3,195,742 Deferred restricted common stock units 668,000 679,000 Deferred restricted common stock awards 226 228 (a) As of September 30, 2022 2021, 1 not (b) Each share of Series C convertible preferred stock was convertible at any time at the holder’s option into one share of common stock. All Series C convertible preferred stock had been converted into common stock and there were no remaining shares outstanding. In March 2022,
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued Accounting Standards In June 2016, 2016 13, 326 2016 13” not 2016 13 December 15, 2022 We have reviewed other recent accounting pronouncements and concluded they are either not no

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2022
Notes Tables
Revenue from External Customers by Geographic Areas [Table Text Block]	Three Months Ended Nine Months Ended September 30, September 30, 2022 2021 2022 2021 North America $ 973 $ 939 $ 2,844 $ 2,857 Asia Pacific 708 677 2,270 1,855 Europe and Middle East 3 - 6 8 Total $ 1,684 $ 1,616 $ 5,120 $ 4,720
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Nine Months Ended September 30, 2022 2021 Convertible preferred stock: Series B convertible preferred stock (a) 2,902,810 2,567,255 Series C convertible preferred stockStockholders’ (b) - - Warrants to purchase common stock 9,793,599 9,793,599 Stock options to purchase common stock 4,105,706 3,195,742 Deferred restricted common stock units 668,000 679,000 Deferred restricted common stock awards 226 228

Note 5 - Accrued Liabilities (T

Note 5 - Accrued Liabilities (Tables)	9 Months Ended
	Sep. 30, 2022
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	September 30, December 31, 2022 2021 Accrued interest $ 1,229 $ - Accrued bonuses 906 1,209 Accrued payroll and other related expenses 557 495 Deferred revenue - subscription rental program 412 448 Accrued professional fees 332 120 Current operating lease liabilities 253 225 Accrued clinical trial costs 248 337 Other accruals 164 219 Total accrued liabilities $ 4,101 $ 3,053

Note 6 - Note Payable (Tables)

Note 6 - Note Payable (Tables)	9 Months Ended
	Sep. 30, 2022
The 2017 Loan Agreement [Member]
Notes Tables
Schedule of Debt [Table Text Block]	Year Ending December 31, 2022 (remaining three months) $ - 2023 5,992 Total payments 5,992 Less: Amount representing interest (362 ) Present value of obligations 5,630 Less: Unamortized debt discount (2 ) Note payable, current portion $ 5,628

Note 8 - Leases (Tables)

Note 8 - Leases (Tables)	9 Months Ended
	Sep. 30, 2022
Notes Tables
Lessee, Lease Assets and Liabilities [Table Text Block]	September 30, December 31, 2022 2021 Assets: Operating lease right-of-use assets $ 370 $ 534 Liabilities: Current operating lease liabilities $ 253 $ 225 Noncurrent operating lease liabilities 133 327 $ 386 $ 552
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Year Ending December 31, 2022 (remaining three months) $ 71 2023 287 2024 67 Total lease payments 425 Less: Amount representing interest (39 ) Present value of lease liabilities $ 386
Lessor, Operating Lease, Payment to be Received, Fiscal Year Maturity [Table Text Block]	Year Ending December 31, 2022 (remaining three months) $ 202 2023 210 Total $ 412

Note 11 - Common Stock (Tables)

Note 11 - Common Stock (Tables)	9 Months Ended
	Sep. 30, 2022
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Number of Shares Outstanding Exercisable Expiration Exercise Under Issuance Date for Date Price Warrants February 2015 Common Shares February 17, 2025 $ 4,000.00 79 March 2015 Common Shares March 26, 2025 $ 2,720.00 2 May 2015 Common Shares May 12, 2025 $ 4,240.00 37 December 2015 Common Shares December 16, 2025 $ 5,600.00 31 April 2016 Common Shares April 1, 2026 $ 6,080.00 25 June 2016 Common Shares June 20, 2026 $ 4,980.00 101 May 2017 Common Shares May 25, 2027 $ 9,500.00 223 November 2019 Common Shares November 26, 2024 $ 18.36 989,379 November 2019 Common Shares November 26, 2024 $ 2.82 285,632 April 2020 Common Shares April 21, 2025 $ 2.82 413,210 January 2021 Common Shares January 19, 2026 $ 3.40 8,104,880 9,793,599
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	Immediately Immediately before After Series B Warrants Modification Modification Exercise price $ 6.10 $ 3.40 Common stock price $ 3.19 $ 3.19 Expected term (in years) 3.9 3.9 Average volatility 90 % 90 % Risk-free interest rate 0.33 % 0.33 % Dividend yield 0 % 0 % Immediately Immediately before After Series A-2 and B-2 Warrants Modification Modification Exercise price $ 6.37 $ 3.40 Common stock price $ 3.19 $ 3.19 Expected term (in years) 4.3 4.3 Average volatility 90 % 90 % Risk-free interest rate 0.33 % 0.33 % Dividend yield 0 % 0 % Immediately Immediately before After Series B, A-2 and B-2 Warrants Modification Modification Exercise price $ 3.40 $ 2.82 Common stock price $ 3.01 $ 3.01 Expected term (in years) 3.6 3.6 Average volatility 80 % 80 % Risk-free interest rate 0.58 % 0.58 % Dividend yield 0 % 0 %

Note 12 - Summary of Stock Op_2

Note 12 - Summary of Stock Options (Tables)	9 Months Ended
	Sep. 30, 2022
Notes Tables
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	Nine Months Ended September 30, 2022 Weighted Weighted Average Number Average Remaining Aggregate of Exercise Contractual Intrinsic Shares Price Term (years) Value Options outstanding, January 1, 2022 3,173,103 $ 7.51 9.0 $ - Options granted 959,000 $ 1.25 Options exercised - Options canceled (26,397 ) $ 8.02 Options outstanding, September 30, 2022 4,105,706 $ 6.05 8.5 $ 80 Vested and exercisable and expected to vest, September 30, 2022 3,895,519 $ 6.24 8.5 $ 71 Vested and exercisable, September 30, 2022 1,521,946 $ 11.45 8.1 $ -
Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]	Weighted Number Weighted Average Number Weighted Outstanding Average Remaining Exercisable Average Range of as of Exercise Contractual as of Exercise Exercise Prices September 30, 2022 Price Term (Years) September 30, 2022 Price $0.66 - $1.26 953,167 $ 1.25 9.3 157,712 $ 1.26 $2.28 - $2.96 2,196,021 $ 2.73 8.7 688,362 $ 2.73 $3.06 - $3.40 10,000 $ 3.20 8.5 3,771 $ 3.20 $4.45 - $4.80 11,900 $ 4.72 8.2 5,319 $ 4.71 $5.10 - $5.40 88,000 $ 5.28 8.0 63,250 $ 5.34 $6.90 - $6.90 5,400 $ 6.90 7.5 3,376 $ 6.90 $8.60 - $8.91 822,332 $ 8.69 7.1 583,220 $ 8.69 $10.90 - $13.60 15,500 $ 12.64 7.4 13,553 $ 12.89 $380.00 - $9,920.00 3,386 $ 2,869.31 5.5 3,383 $ 2,870.91 Total: 4,105,706 $ 6.05 8.5 1,521,946 $ 11.45
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Three Months Ended Nine Months Ended September 30, September 30, 2022 2021 2022 2021 Expected term (in years) 6 5 6 6 Average volatility 89 % 84 % 88 % 76 % Risk-free interest rate 2.69 % 0.81 % 1.46 % 0.97 % Dividend yield 0 % 0 % 0 % 0 %
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three Months Ended Nine Months Ended September 30, September 30, 2022 2021 2022 2021 Cost of revenue $ 64 $ 76 $ 193 $ 191 Research and development 118 131 361 330 Selling, general and administrative 686 881 2,183 2,244 Total $ 868 $ 1,088 $ 2,737 $ 2,765

Note 1 - The Company and Basi_2

Note 1 - The Company and Basis of Presentation (Details Textual) - USD ($)						1 Months Ended	2 Months Ended	3 Months Ended		6 Months Ended	9 Months Ended
	Jul. 02, 2021	May 04, 2021	Jan. 19, 2021	Jun. 09, 2020	Jun. 08, 2020	Feb. 28, 2021	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021	Jun. 30, 2022	Sep. 30, 2022	Sep. 30, 2021	Mar. 31, 2022	Mar. 14, 2022	Dec. 31, 2021	May 03, 2021	Jan. 31, 2021	Jan. 18, 2021
Fair Value Adjustment of Warrants								$ 0	$ 0		$ 0	$ 373,000
Proceeds from Warrant Exercises											$ 0	179,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)								9,793,599			9,793,599
Preferred Stock, Shares Authorized (in shares)								10,000,000			10,000,000				10,000,000
Retained Earnings (Accumulated Deficit), Total								$ (258,514,000)			$ (258,514,000)				$ (241,853,000)
Cash and Cash Equivalents, at Carrying Value, Total								5,907,000			5,907,000				$ 19,162,000
Working Capital								1,233,000			1,233,000
Net Cash Provided by (Used in) Operating Activities, Total											(13,005,000)	$ (9,651,000)
The 2017 Loan Agreement [Member]
Long-Term Debt, Gross								$ 5,628,000			$ 5,628,000
Series B Preferred Stock [Member]
Stock Issued During Period, Shares, Warrant Exercises (in shares)							40,000
Proceeds from Warrant Exercises							$ 136,000
Preferred Stock, Shares Outstanding, Ending Balance (in shares)								44,413	39,279		44,413	39,279			40,504
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)								2,902,810	2,567,255		2,902,810	2,567,255			2,647,320
January 2021 Offering Warrants [Member]
Stock Issued During Period, Shares, Warrant Exercises (in shares)							12,760
Proceeds from Warrant Exercises							$ 43,000
Common Stock [Member] | Lincoln Park Capital [Member]
Stock Issued During Period, Shares, New Issues (in shares)		250,000
Share Price (in dollars per share)		$ 2.817
Series B Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)								285,632			285,632
Series A-2 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)								392,830			392,830
Series B-2 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)								20,380			20,380
Series C Preferred Stock [Member]
Preferred Stock, Shares Outstanding, Ending Balance (in shares)								0			0			0	0		0
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)								1			1
Preferred Stock, Shares Authorized (in shares)														2,450,880
Series A and Series B Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 3.40
Fair Value Adjustment of Warrants			$ 287,000
Series B Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 3.40															$ 6.10
Stock Issued During Period, Shares, Warrant Exercises (in shares)						40,000
Proceeds from Warrant Exercises						$ 136,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)								285,632			285,632
Series A-2 and Series B-2 Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 2.817	$ 3.40													$ 3.40		$ 6.371
Fair Value Adjustment of Warrants		$ 86,000	$ 287,000
Class of Warrant or Right, Change to Quantity of Warrant Shares (in shares)		0
Warrants Issued in Connection with Class A Units [Member] | Class A Units [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 3.40
Warrants Per Unit (in shares)			1
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)			1
Warrants and Rights Outstanding, Term (Year)			5 years
Warrants Issued in Connection with Class B Units [Member] | Class B Units [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 3.40
Warrants Per Unit (in shares)			1
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)			1
Warrants and Rights Outstanding, Term (Year)			5 years
Warrants Issued in Connection with January 2021 Offering [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)																	$ 3.40
Stock Issued During Period, Shares, Warrant Exercises (in shares)							12,760
Proceeds from Warrant Exercises							$ 43,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			8,117,640					8,104,880			8,104,880						8,117,640
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)																	1
Warrants and Rights Outstanding, Term (Year)																	5 years
Universal Shelf Registration Statement [Member]
Universal Shelf Registration Statement, Proposed Maximum Securities Offering	$ 75,000,000
Universal Shelf Registration Statement, Maximum Capacity													$ 75,000,000
Stock Issued During Period, Shares, New Issues (in shares)										0
January 2021 Offering [Member]
Proceeds from Issuance or Sale of Equity, Total			$ 27,600,000
Shares Issued, Price Per Share (in dollars per share)			$ 3.40
Proceeds from Issuance or Sale of Equity, Net of Issuance Costs			$ 25,122,000
January 2021 Offering [Member] | Class A Units [Member]
Units Issued, Shares (in shares)			4,607,940
Shares Issued, Price Per Share (in dollars per share)			$ 3.40
Common Shares Per Unit (in shares)			1
Warrants Per Unit (in shares)			1
January 2021 Offering [Member] | Class B Units [Member]
Units Issued, Shares (in shares)			2,450,880
Shares Issued, Price Per Share (in dollars per share)			$ 3.40
Warrants Per Unit (in shares)			1
Series C Convertible Preferred Stock Per Unit (in shares)			1
January 2021 Offering [Member] | Series C Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)			2,450,880
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)								1			1
Over-Allotment Option [Member]
Stock Issued During Period, Shares, New Issues (in shares)			1,058,820
Over-Allotment Option [Member] | Warrants Issued in Connection with January 2021 Offering [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			1,058,820
Purchase Agreement with LPC [Member]
Stock Issued During Period, Shares, New Issues (in shares)		250,000		52,500
Shares Issued, Price Per Share (in dollars per share)		$ 2.817		$ 6.50
Maximum Amount of Shares Issuable					$ 10,000,000
Stock Purchase Agreement Duration Period (Month)					30 months
Equity Facility, Remaining Financing Commitment								$ 9,000,000		$ 9,000,000	$ 9,000,000

Note 2 - Summary of Significa_3

Note 2 - Summary of Significant Accounting Policies (Details Textual)	3 Months Ended				9 Months Ended		12 Months Ended
	Sep. 30, 2022 USD ($) $ / shares shares	Jun. 30, 2022 USD ($)	Mar. 31, 2022 USD ($)	Sep. 30, 2021 USD ($) shares	Sep. 30, 2022 USD ($) $ / shares shares	Sep. 30, 2021 USD ($) shares	Dec. 31, 2021 USD ($) shares	Mar. 14, 2022 shares	Jan. 31, 2021 shares
Number of Financial Institutions	1				1
Accounts Receivable, Allowance for Credit Loss, Writeoff	$ 2,000			$ 115,000	$ 60,000	$ 179,000
Revenue from Contract with Customer, Excluding Assessed Tax	1,684,000			1,616,000	5,120,000	4,720,000
Contract with Customer, Asset, after Allowance for Credit Loss, Total	0				0		$ 0
Contract with Customer, Liability, Total	7,000				7,000		7,000
Capitalized Contract Cost, Net, Total	60,000				60,000		$ 84,000
Capitalized Contract Cost, Amortization	24,000			13,000	61,000	47,000
Capitalized Contract Cost, Impairment Loss					0
Equity Method Investment, Other than Temporary Impairment	$ 0			$ 0	$ 455,000	$ 0
Series B Preferred Stock [Member]
Preferred Stock, Shares Outstanding, Ending Balance (in shares) | shares	44,413			39,279	44,413	39,279	40,504
Convertible Preferred Stock, Shares Issued upon Conversion (in shares) | shares	2,902,810			2,567,255	2,902,810	2,567,255	2,647,320
Series B Preferred Stock [Member] | Conversion From Series B Preferred Stock to Common Stock [Member]
Preferred Stock, Convertible, Conversion Ratio	65.36				65.36
Preferred Stock, Liquidation Preference Per Share (in dollars per share) | $ / shares	$ 1,000				$ 1,000
Preferred Stock, Convertible, Conversion Price (in dollars per share) | $ / shares	$ 15.30				$ 15.30
Series C Preferred Stock [Member]
Preferred Stock, Shares Outstanding, Ending Balance (in shares) | shares	0				0		0	0	0
Convertible Preferred Stock, Shares Issued upon Conversion (in shares) | shares	1				1
InControl Medical [Member]
Equity Method Investment, Other than Temporary Impairment	$ 0	$ 455,000	$ 0				$ 0
Rental [Member]
Revenue from Contract with Customer, Excluding Assessed Tax	265,000			$ 261,000	$ 799,000	$ 950,000
Contract with Customer, Liability, Current	412,000				412,000		$ 452,000
Contract with Customer, Liability, Revenue Recognized	$ 73,000			$ 14,000	$ 388,000	$ 310,000
Minimum [Member]
Warranty Period (Year)					1 year
Minimum [Member] | Viveve Systems [Member]
Lessor, Operating Lease, Term of Contract (Month)	6 months				6 months
Maximum [Member]
Warranty Period (Year)					3 years
Maximum [Member] | Viveve Systems [Member]
Lessor, Operating Lease, Term of Contract (Month)	12 months				12 months
Customer Concentration Risk [Member] | Revenue Benchmark [Member]
Concentration Risk, Number of Customers	2			1	1	1	1
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Two Customers [Member]
Concentration Risk, Percentage	36%
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | One Customer [Member]
Concentration Risk, Percentage	31%			36%		29%
Customer Concentration Risk [Member] | Accounts Receivable [Member]
Concentration Risk, Number of Customers					2
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Two Customers [Member]
Concentration Risk, Percentage					45%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | One Customer [Member]
Concentration Risk, Percentage							10%

Note 2 - Summary of Significa_4

Note 2 - Summary of Significant Accounting Policies - Revenue From Unaffiliated Customers by Geographic Area (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenue	$ 1,684	$ 1,616	$ 5,120	$ 4,720
North America [Member]
Revenue	973	939	2,844	2,857
Asia Pacific [Member]
Revenue	708	677	2,270	1,855
Europe And Middle East [Member]
Revenue	$ 3	$ 0	$ 6	$ 8

Note 2 - Summary of Significa_5

Note 2 - Summary of Significant Accounting Policies - Antidilutive Securities (Details) - shares		9 Months Ended
		Sep. 30, 2022	Sep. 30, 2021
Series B Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares)	[1]	2,902,810	2,567,255
Series C Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares)	[2]	0	0
Common Stock Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares)		9,793,599	9,793,599
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares)		4,105,706	3,195,742
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares)		668,000	679,000
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares)		226	228
[1]As of September 30, 2022 and 2021, a total of 44,413 and 39,279 shares of Series B convertible preferred stock were outstanding and convertible into 2,902,810 and 2,567,255 shares of common stock, respectively. Each share of Series B convertible preferred stock is convertible at the holder's option into shares of common stock at a conversion ratio of 1-for-65.36 per share determined by dividing the Series B liquidation amount of $1,000 per share by the Series B conversion price of $15.30 per share. However, under the terms of the Series B Preferred Stock and Warrant Purchase Agreement, as amended, CRG LP (“CRG”) will not convert the Series B preferred stock or exercise the CRG warrants until the Company’s stockholders act to authorize additional number of shares of common stock sufficient to cover the conversion shares.[2]Each share of Series C convertible preferred stock was convertible at any time at the holder's option into one share of common stock. All Series C convertible preferred stock had been converted into common stock and there were no remaining shares outstanding. In March 2022, the Company filed a Certificate of Elimination with the Delaware Secretary of State with respect to the authorized shares of Series C convertible preferred stock.

Note 4 - Investment in Uncons_2

Note 4 - Investment in Unconsolidated Limited Liability Company (Details Textual)		3 Months Ended				6 Months Ended	9 Months Ended		12 Months Ended	62 Months Ended
	Aug. 08, 2017 USD ($)	Sep. 30, 2022 USD ($)	Jun. 30, 2022 USD ($)	Mar. 31, 2022 USD ($)	Sep. 30, 2021 USD ($)	Jun. 30, 2022 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)	Sep. 30, 2022 USD ($)
Income (Loss) from Equity Method Investments		$ 0			$ (33,000)		$ (122,000)	$ (188,000)
Equity Method Investment, Other than Temporary Impairment		0			0		455,000	0
Equity Method Investments		0					0		$ 577,000	$ 0
InControl Medical [Member]
Income (Loss) from Equity Method Investments		0			$ 33,000		$ (122,000)	$ (188,000)
Equity Method Investment, Other than Temporary Impairment		$ 0	$ 455,000	$ 0					0
Equity Method Investments			$ 0			$ 0
InControl Medical [Member] | Membership Unit Subscription Agreement [Member]
Payments to Acquire Equity Method Investments	$ 2,500,000
Equity Method Investment, Ownership Percentage		7%					7%			7%
Unrecorded Unconditional Purchase Obligation, Period Quantity Purchased		0			40		0	140		5,425
Unrecorded Unconditional Purchase Obligation, Purchases		$ 0			$ 5,000	$ 0	$ 0	$ 17,000
Unrecorded Unconditional Purchase Obligation, Purchases, Product Cost		0			$ 7,000
Accounts Payable, Related Parties, Current		$ 0					$ 0		$ 0	$ 0

Note 5 - Accrued Liabilities -

Note 5 - Accrued Liabilities - Accrued Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Accrued interest	$ 1,229	$ 0
Accrued bonuses	906	1,209
Accrued payroll and other related expenses	557	495
Deferred revenue - subscription rental program	412	448
Accrued professional fees	332	120
Accrued clinical trial costs	248	337
Other accruals	164	219
Total accrued liabilities	4,101	3,053
Accrued Liabilities [Member]
Current operating lease liabilities	$ 253	$ 225

Note 6 - Note Payable (Details

Note 6 - Note Payable (Details Textual) - USD ($)				3 Months Ended		9 Months Ended
	Nov. 12, 2019	Dec. 29, 2017	May 22, 2017	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)				9,793,599		9,793,599
Notes Payable, Current, Total				$ 5,628,000		$ 5,628,000		$ 0
Notes Payable, Noncurrent, Total				0		0		5,124,000
Series B Convertible Preferred Stock Into Common Stock [Member] | Minimum [Member]
Conversion of Stock, Conversion Rate (in dollars per share)	$ 15.30
Series B Convertible Preferred Stock Into Common Stock [Member] | Maximum [Member]
Conversion of Stock, Conversion Rate (in dollars per share)	$ 18.36
Conversion of Term Loan with CRG Into Stock and Warrants [Member]
Debt Conversion, Original Debt, Amount	$ 28,981,000
Debt Conversion, Converted Instrument, Amount	$ 31,300,000
Conversion of Term Loan with CRG Into Series B Convertible Preferred Stock [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares)	31,300
May 2017 Issuance Related to 2017 Loan Agreement [Member]
Warrants and Rights Outstanding, Term (Year)			10 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			223
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 9,500
Warrants Issued Upon Conversion of Term Loan with CRG [Member]
Warrants and Rights Outstanding, Term (Year)	5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	989,379
Class of Warrants and Rights Outstanding, Exercise Price Percentage of Conversion Rate	120%
The 2017 Loan Agreement [Member]
Notes Payable, Current, Total				5,628,000		5,628,000
The 2017 Loan Agreement [Member] | CRG LP [Member]
Debt Instrument, Face Amount			$ 20,000,000
Debt Agreement, Covenant, Additional Funding			10,000,000
Debt Agreement, Maximum Borrowing Capacity			$ 30,000,000
Proceeds from Lines of Credit, Total		$ 10,000,000
Debt Instrument, Term (Year)			6 years
Debt instrument, Interest Only Payment, Period (Year)			4 years
Debt Instrument, Interest Rate, Stated Percentage			12.50%
Debt Instrument, Interest Rate, Stated Percentage Deferred During Interest-only Period			4%
Debt Instrument, Prepayment Fee, Percentage			5%
Debt Instrument, Back-end Facility Fee Percentage of Principal	25%		5%
Paid-in-Kind Interest				175,000	$ 154,000	502,000	$ 443,000
Notes Payable, Current, Total				$ 5,628,000		$ 5,628,000
Notes Payable, Noncurrent, Total								$ 5,124,000

Note 6 - Note Payable - Summary

Note 6 - Note Payable - Summary of Note Payable (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021	Sep. 30, 2021
Less: Unamortized debt discount	$ (2,000)		$ (3,000)
Note payable, current portion	5,628,000	$ 0
The 2017 Loan Agreement [Member]
2022 (remaining three months)	0
2023	5,992,000
Total payments	5,992,000
Less: Amount representing interest	(362,000)
Present value of obligations	5,630,000
Less: Unamortized debt discount	(2,000)
Note payable, current portion	$ 5,628,000

Note 7 - Paycheck Protection _2

Note 7 - Paycheck Protection Program Loan (Details Textual) - USD ($)			3 Months Ended		9 Months Ended
	May 25, 2021	Apr. 24, 2020	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Gain (Loss) on Extinguishment of Debt, Total			$ 0	$ 0	$ 0	$ 1,358,000
Paycheck Protection Program CARES Act [Member]
Proceeds from Issuance of Unsecured Debt		$ 1,343,000
Gain (Loss) on Extinguishment of Debt, Total	$ 1,358,000

Note 8 - Leases (Details Textua

Note 8 - Leases (Details Textual)	1 Months Ended	3 Months Ended		9 Months Ended
	Jun. 30, 2021 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Mar. 31, 2021	Oct. 01, 2020	Feb. 01, 2017 USD ($) ft²
Operating Lease, Expense		$ 69,000	$ 69,000	$ 207,000	$ 211,000
Operating Lease, Weighted Average Discount Rate, Percent		12.50%		12.50%
Sublease Agreement for Relocation of Headquarters [Member]
Lessee, Operating Lease, Term of Contract (Month)								36 months
Area of Real Estate Property (Square Foot) | ft²								12,400
Security Deposit								$ 22,000
Operating Leases, Allowance for Certain Improvements								$ 88,000
Lessee, Operating Lease, Renewal Term (Month)						34 months
Lessee, Operating Lease, Rent Abatement	$ 19,000
Noncancelable Operating Lease Agreement for Office Equipment [Member]
Lessee, Operating Lease, Term of Contract (Month)							36 months
Leases of Viveve Systems [Member]
Property, Plant, and Equipment, Lessor Asset under Operating Lease, after Accumulated Depreciation, Total		$ 338,000		$ 338,000
Depreciation, Lessor Asset under Operating Lease		$ 49,000	$ 68,000	$ 162,000	$ 273,000

Note 8 - Leases - Lease Assets

Note 8 - Leases - Lease Assets and Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Other Assets [Member]
Operating lease right-of-use assets	$ 370	$ 534
Accrued Liabilities [Member]
Current operating lease liabilities	253	225
Other Noncurrent Liabilities [Member]
Noncurrent operating lease liabilities	133	327
Accrued Liabilities and Other Noncurrent Liabilities [Member]
Operating Lease, Liability, Total	$ 386	$ 552

Note 8 - Leases - Maturity of O

Note 8 - Leases - Maturity of Operating Lease Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
2022 (remaining three months)	$ 71
2023	287
2024	67
Total lease payments	425
Less: Amount representing interest	(39)
Accrued Liabilities and Other Noncurrent Liabilities [Member]
Present value of lease liabilities	$ 386	$ 552

Note 8 - Leases - Minimum Futur

Note 8 - Leases - Minimum Future Rentals (Details) $ in Thousands	Sep. 30, 2022 USD ($)
2022 (remaining three months)	$ 202
2023	210
Total	$ 412

Note 10 - Preferred Stock (Deta

Note 10 - Preferred Stock (Details Textual)				3 Months Ended		9 Months Ended		34 Months Ended
	Jan. 19, 2021 shares	Nov. 26, 2019	Nov. 12, 2019 shares	Sep. 30, 2022 USD ($) $ / shares shares	Sep. 30, 2021 USD ($) shares	Sep. 30, 2022 USD ($) $ / shares shares	Sep. 30, 2021 USD ($) shares	Sep. 30, 2022 USD ($) $ / shares shares	Mar. 14, 2022 shares	Dec. 31, 2021 shares	Jan. 31, 2021 shares
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)				9,793,599		9,793,599		9,793,599
Preferred Stock, Shares Authorized (in shares)				10,000,000		10,000,000		10,000,000		10,000,000
Series B Preferred Stock [Member]
Preferred Stock, Dividend Rate, Percentage		12.50%
Preferred Stock Dividends, Shares (in shares)				1,344	1,189	3,909	3,460	13,113
Dividends, Preferred Stock, Cash | $				$ 2,000	$ 1,000	$ 8,000	$ 4,000	$ 24,000
Preferred Stock, Shares Outstanding, Ending Balance (in shares)				44,413	39,279	44,413	39,279	44,413		40,504
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)				2,902,810	2,567,255	2,902,810	2,567,255	2,902,810		2,647,320
Series B Preferred Stock [Member] | Conversion From Series B Preferred Stock to Common Stock [Member]
Preferred Stock, Convertible, Conversion Ratio				65.36		65.36		65.36
Preferred Stock, Liquidation Preference Per Share (in dollars per share) | $ / shares				$ 1,000		$ 1,000		$ 1,000
Preferred Stock, Convertible, Conversion Price (in dollars per share) | $ / shares				$ 15.30		$ 15.30		$ 15.30
Series C Preferred Stock [Member]
Preferred Stock, Shares Outstanding, Ending Balance (in shares)				0		0		0	0	0	0
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)				1		1		1
Preferred Stock, Shares Authorized (in shares)									2,450,880
Series C Preferred Stock [Member] | January 2021 Offering [Member]
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)				1		1		1
Stock Issued During Period, Shares, New Issues (in shares)	2,450,880
Warrants Issued Upon Conversion of Term Loan with CRG [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			989,379
Conversion of Term Loan with CRG Into Series B Convertible Preferred Stock [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares)			31,300

Note 11 - Common Stock (Details

Note 11 - Common Stock (Details Textual) - USD ($)						1 Months Ended		2 Months Ended	3 Months Ended		9 Months Ended
	May 04, 2021	Mar. 31, 2021	Jan. 19, 2021	Jun. 09, 2020	Jun. 08, 2020	Mar. 31, 2021	Feb. 28, 2021	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Jun. 30, 2022	Mar. 14, 2022	Dec. 31, 2021	Jun. 23, 2021	May 03, 2021	Jan. 31, 2021	Jan. 18, 2021	May 22, 2017
Proceeds from Issuance of Common Stock											$ 0	$ 25,122,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)									9,793,599		9,793,599
Proceeds from Warrant Exercises											$ 0	$ 179,000
Stock Issued During Period, Share, Restricted Common Shares (in shares)									0	0	0	0
Amortization of Debt Discount (Premium)									$ 1,000	$ 1,000	$ 3,000
Debt Instrument, Unamortized Discount, Total									2,000	3,000	2,000	$ 3,000
Fair Value Adjustment of Warrants									$ 0	$ 0	$ 0	$ 373,000
Class of Warrant or Right Number of Securities Called by Warrants or Rights Cancelled In Period (in shares)									0	0	0	0
Class Of Warrant Or Right, Number Of Securities Called By Warrants Or Rights Expired In Period (in shares)									0	0	0	6
Series C Preferred Stock [Member]
Preferred Stock, Shares Outstanding, Ending Balance (in shares)									0		0			0	0			0
Warrants Issued in Connection with January 2021 Offering [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)																		1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)																		$ 3.40
Warrants and Rights Outstanding, Term (Year)																		5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			8,117,640						8,104,880		8,104,880							8,117,640
Stock Issued During Period, Shares, Warrant Exercises (in shares)								12,760
Proceeds from Warrant Exercises								$ 43,000
May 2017 Issuance Related to 2017 Loan Agreement [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)																				$ 9,500
Warrants and Rights Outstanding, Term (Year)																				10 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)																				223
Series B Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 3.40																$ 6.10
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)									285,632		285,632
Stock Issued During Period, Shares, Warrant Exercises (in shares)							40,000
Proceeds from Warrant Exercises							$ 136,000
Series A-2 and Series B-2 Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 2.817		$ 3.40														$ 3.40		$ 6.371
Fair Value Adjustment of Warrants	$ 86,000		$ 287,000
Series B, A-2 and B-2 Common Stock Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 2.817																$ 3.40
Fair Value Adjustment of Warrants	$ 86,000
January 2021 Offering Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)													8,104,880
Stock Issued During Period, Shares, Warrant Exercises (in shares)						4,000	8,760
Proceeds from Warrant Exercises						$ 13,000	$ 30,000
Series A Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)									0		0
Series A-2 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)									392,830		392,830
Series B-2 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)									20,380		20,380
Class A Units [Member] | Warrants Issued in Connection with Class A Units [Member]
Warrants Per Unit (in shares)			1
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)			1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 3.40
Warrants and Rights Outstanding, Term (Year)			5 years
Class B Units [Member] | Warrants Issued in Connection with Class B Units [Member]
Warrants Per Unit (in shares)			1
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)			1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 3.40
Warrants and Rights Outstanding, Term (Year)			5 years
Purchase Agreement with LPC [Member]
Maximum Amount of Shares Issuable					$ 10,000,000
Stock Purchase Agreement Duration Period (Month)					30 months
Stock Purchase Agreement, Maximum Issuable Shares (in shares)					301,762
Stock Purchase Agreement, Maximum Issuable Shares, Percent of Outstanding Stock					19.99%
Stock Purchase Agreement, Share Price Covenant Trigger (in dollars per share)					$ 6.46
Stock Issued During Period, Shares, New Issues (in shares)	250,000			52,500
Shares Issued, Price Per Share (in dollars per share)	$ 2.817			$ 6.50
Proceeds from Issuance of Common Stock				$ 341,000
Payments of Stock Issuance Costs				$ 494,000							$ 0	$ 71,000
Equity Facility, Remaining Financing Commitment									$ 9,000,000		$ 9,000,000		$ 9,000,000
First Amendment to the LPC Purchase Agreement [Member]
Stock Purchase Agreement, Maximum Issuable Shares (in shares)		2,068,342				2,068,342		2,068,342
Stock Purchase Agreement, Maximum Issuable Shares, Percent of Outstanding Stock		19.99%				19.99%		19.99%								20%
Stock Purchase Agreement, Share Price Covenant Trigger (in dollars per share)		$ 2.99				$ 2.99		$ 2.99
Stock Issued During Period, Shares, New Issues (in shares)	250,000
Shares Issued, Price Per Share (in dollars per share)	$ 2.817
Proceeds from Issuance of Common Stock	$ 704,000
Payments of Stock Issuance Costs		$ 70,000
January 2021 Offering [Member]
Shares Issued, Price Per Share (in dollars per share)			$ 3.40
Proceeds from Issuance or Sale of Equity, Total			$ 27,600,000
Proceeds from Issuance or Sale of Equity, Net of Issuance Costs			$ 25,122,000
January 2021 Offering [Member] | Series C Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)			2,450,880
January 2021 Offering [Member] | Class A Units [Member]
Shares Issued, Price Per Share (in dollars per share)			$ 3.40
Units Issued, Shares (in shares)			4,607,940
Common Shares Per Unit (in shares)			1
Warrants Per Unit (in shares)			1
January 2021 Offering [Member] | Class B Units [Member]
Shares Issued, Price Per Share (in dollars per share)			$ 3.40
Units Issued, Shares (in shares)			2,450,880
Warrants Per Unit (in shares)			1
January 2021 Offering [Member] | Class B Units [Member] | Series C Convertible Preferred Stock [Member]
Preferred Units, Authorized (in shares)			1
Over-Allotment Option [Member]
Stock Issued During Period, Shares, New Issues (in shares)			1,058,820
Over-Allotment Option [Member] | Warrants Issued in Connection with January 2021 Offering [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			1,058,820

Note 11 - Common Stock - Summar

Note 11 - Common Stock - Summary of Outstanding Warrants (Details)	9 Months Ended
	Sep. 30, 2022 $ / shares shares
Shares Outstanding Under Warrants (in shares)	9,793,599
Warrant One [Member]
Expiration Date	Feb. 17, 2025
Exercise Price (in dollars per share) | $ / shares	$ 4,000
Shares Outstanding Under Warrants (in shares)	79
Warrant Two [Member]
Expiration Date	Mar. 26, 2025
Exercise Price (in dollars per share) | $ / shares	$ 2,720
Shares Outstanding Under Warrants (in shares)	2
Warrant Three [Member]
Expiration Date	May 12, 2025
Exercise Price (in dollars per share) | $ / shares	$ 4,240
Shares Outstanding Under Warrants (in shares)	37
Warrant Four [Member]
Expiration Date	Dec. 16, 2025
Exercise Price (in dollars per share) | $ / shares	$ 5,600
Shares Outstanding Under Warrants (in shares)	31
Warrant Five [Member]
Expiration Date	Apr. 01, 2026
Exercise Price (in dollars per share) | $ / shares	$ 6,080
Shares Outstanding Under Warrants (in shares)	25
Range Six [Member]
Expiration Date	Jun. 20, 2026
Warrant Six [Member]
Exercise Price (in dollars per share) | $ / shares	$ 4,980
Shares Outstanding Under Warrants (in shares)	101
Warrant Seven [Member]
Expiration Date	May 25, 2027
Exercise Price (in dollars per share) | $ / shares	$ 9,500
Shares Outstanding Under Warrants (in shares)	223
Warrant Eight [Member]
Expiration Date	Nov. 26, 2024
Exercise Price (in dollars per share) | $ / shares	$ 18.36
Shares Outstanding Under Warrants (in shares)	989,379
Warrant Nine [Member]
Expiration Date	Nov. 26, 2024
Exercise Price (in dollars per share) | $ / shares	$ 2.82
Shares Outstanding Under Warrants (in shares)	285,632
Warrant Ten [Member]
Expiration Date	Apr. 21, 2025
Exercise Price (in dollars per share) | $ / shares	$ 2.82
Shares Outstanding Under Warrants (in shares)	413,210
Warrant Eleven [Member]
Expiration Date	Jan. 19, 2026
Exercise Price (in dollars per share) | $ / shares	$ 3.40
Shares Outstanding Under Warrants (in shares)	8,104,880

Note 11 - Common Stock - Assump

Note 11 - Common Stock - Assumptions (Details) - Warrant [Member]	May 05, 2021	May 04, 2021	Jan. 19, 2021	Jan. 18, 2021
Measurement Input, Exercise Price [Member] | Series B Warrants [Member]
Warrants and Rights Outstanding, Measurement Input			3.40	6.10
Measurement Input, Exercise Price [Member] | Series A-2 and Series B-2 Warrants [Member]
Warrants and Rights Outstanding, Measurement Input	2.82	3.40	3.40	6.37
Measurement Input, Share Price [Member] | Series B Warrants [Member]
Warrants and Rights Outstanding, Measurement Input			3.19	3.19
Measurement Input, Share Price [Member] | Series A-2 and Series B-2 Warrants [Member]
Warrants and Rights Outstanding, Measurement Input	3.01	3.01	3.19	3.19
Measurement Input, Expected Term [Member] | Series B Warrants [Member]
Warrants and Rights Outstanding, Measurement Input			3.9	3.9
Measurement Input, Expected Term [Member] | Series A-2 and Series B-2 Warrants [Member]
Warrants and Rights Outstanding, Measurement Input	3.6	3.6	4.3	4.3
Measurement Input, Price Volatility [Member] | Series B Warrants [Member]
Warrants and Rights Outstanding, Measurement Input			0.90	0.90
Measurement Input, Price Volatility [Member] | Series A-2 and Series B-2 Warrants [Member]
Warrants and Rights Outstanding, Measurement Input	0.80	0.80	0.90	0.90
Measurement Input, Risk Free Interest Rate [Member] | Series B Warrants [Member]
Warrants and Rights Outstanding, Measurement Input			0.0033	0.0033
Measurement Input, Risk Free Interest Rate [Member] | Series A-2 and Series B-2 Warrants [Member]
Warrants and Rights Outstanding, Measurement Input	0.0058	0.0058	0.0033	0.0033
Measurement Input, Expected Dividend Rate [Member] | Series B Warrants [Member]
Warrants and Rights Outstanding, Measurement Input			0	0
Measurement Input, Expected Dividend Rate [Member] | Series A-2 and Series B-2 Warrants [Member]
Warrants and Rights Outstanding, Measurement Input	0	0	0	0

Note 12 - Summary of Stock Op_3

Note 12 - Summary of Stock Options (Details Textual) - USD ($) $ / shares in Units, Pure in Thousands		1 Months Ended	3 Months Ended				9 Months Ended		12 Months Ended
	Jan. 01, 2022	Jan. 31, 2021	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	May 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)			4,105,706				4,105,706		3,173,103
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share)			$ 6.05				$ 6.05		$ 7.51
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year)							8 years 6 months		9 years
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)							959,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate			0%			0%	0%	0%
Employees and Nonemployees [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)			4,000			30,400	959,000	2,251,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)			$ 0.43			$ 1.60	$ 0.92	$ 1.75
Restricted Stock Units (RSUs) [Member]
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total			$ 327,000				$ 327,000
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)							3 months 18 days
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)							2 years
Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate							0%
Dividend, Share-Based Payment Arrangement, Total							$ 0
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total			$ 4,755,788				$ 4,755,788
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)							2 years 4 months 24 days
The 2006 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)			12				12
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)			0				0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share)			$ 9,920				$ 9,920
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year)							3 months 18 days
The 2013 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)			4,105,694				4,105,694
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)			244,624				244,624
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share)			$ 6.02				$ 6.02
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year)							8 years 6 months
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares)	1,076,833
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)	5,016,969								3,940,136
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance (in shares)			668,000				668,000
The 2013 Plan [Member] | Restricted Stock Units (RSUs) [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance (in shares)			226				226
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)			0				0
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period (in shares)			6,000			5,000	6,000	11,000
The 2013 Plan [Member] | Restricted Stock Units (RSUs) [Member] | Employees and Board Members [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)		690,000
The 2013 Plan [Member] | Restricted Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)			0			0	0	0
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period (in shares)			2			4	2	6
2017 Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)			392,859				392,859
Common Stock, Capital Shares Reserved for Future Issuance (in shares)						500,378		500,378		400
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant During Offering Period (in shares)						2,000		2,000		2
Stock Issued During Period, Shares, Employee Stock Purchase Plans (in shares)			33,815	24,505	20,691	10,844
Shares Issued, Price Per Share (in dollars per share)			$ 0.54	$ 0.56	$ 0.90	$ 1.94	$ 0.54	$ 1.94

Note 12 - Summary of Stock Op_4

Note 12 - Summary of Stock Options - Summary of Option Activity Under All Plans (Details) $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2022 USD ($) $ / shares shares	Dec. 31, 2021 USD ($) $ / shares shares
Options outstanding (in shares) | shares	3,173,103
Options outstanding, weighted average exercise price (in dollars per share) | $ / shares	$ 7.51
Options outstanding, weighted average remaining contractual term (Year)	8 years 6 months	9 years
Options outstanding, aggregate intrinsic value | $	$ 80	$ 0
Options granted (in shares) | shares	959,000
Options granted, weighted average exercise price (in dollars per share) | $ / shares	$ 1.25
Options exercised (in shares) | shares	0
Options exercised, weighted average exercise price (in dollars per share) | $ / shares
Options canceled (in shares) | shares	(26,397)
Options canceled, weighted average exercise price (in dollars per share) | $ / shares	$ 8.02
Options outstanding (in shares) | shares	4,105,706	3,173,103
Options outstanding, weighted average exercise price (in dollars per share) | $ / shares	$ 6.05	$ 7.51
Vested and exercisable and expected to vest (in shares) | shares	3,895,519
Vested and exercisable and expected to vest, end of period, weighted average exercise price (in dollars per share) | $ / shares	$ 6.24
Vested and exercisable and expected to vest, end of period, weighted average remaining contractual term (Year)	8 years 6 months
Vested and exercisable and expected to vest, end of period, aggregate intrinsic value | $	$ 71
Vested and exercisable (in shares) | shares	1,521,946
Vested and exercisable, end of period, weighted average exercise price (in dollars per share) | $ / shares	$ 11.45
Vested and exercisable, end of period, weighted average remaining contractual term (Year)	8 years 1 month 6 days
Vested and exercisable, end of period, aggregate intrinsic value | $	$ 0

Note 12 - Summary of Stock Op_5

Note 12 - Summary of Stock Options - Summary of Options Outstanding and Exercisable (Details)	9 Months Ended
	Sep. 30, 2022 $ / shares shares
Options outstanding, number (in shares) | shares	4,105,706
Options outstanding, weighted average exercise price (in dollars per share)	$ 6.05
Options outstanding, weighted average remaining contractual term (Year)	8 years 6 months
$0.66Options exercisable, number exercisable (in shares) | shares	1,521,946
Options exercisable, weighted average exercise price (in dollars per share)	$ 11.45
Range One [Member]
Exercise price range, lower limit (in dollars per share)	0
Exercise price range, upper limit (in dollars per share)	$ 1.26
Options outstanding, number (in shares) | shares	953,167
Options outstanding, weighted average exercise price (in dollars per share)	$ 1.25
Options outstanding, weighted average remaining contractual term (Year)	9 years 3 months 18 days
$0.66Options exercisable, number exercisable (in shares) | shares	157,712
Options exercisable, weighted average exercise price (in dollars per share)	$ 1.26
Range Two [Member]
Exercise price range, lower limit (in dollars per share)	2.28
Exercise price range, upper limit (in dollars per share)	$ 2.96
Options outstanding, number (in shares) | shares	2,196,021
Options outstanding, weighted average exercise price (in dollars per share)	$ 2.73
Options outstanding, weighted average remaining contractual term (Year)	8 years 8 months 12 days
$0.66Options exercisable, number exercisable (in shares) | shares	688,362
Options exercisable, weighted average exercise price (in dollars per share)	$ 2.73
Range Three [Member]
Exercise price range, lower limit (in dollars per share)	3.06
Exercise price range, upper limit (in dollars per share)	$ 3.40
Options outstanding, number (in shares) | shares	10,000
Options outstanding, weighted average exercise price (in dollars per share)	$ 3.20
Options outstanding, weighted average remaining contractual term (Year)	8 years 6 months
$0.66Options exercisable, number exercisable (in shares) | shares	3,771
Options exercisable, weighted average exercise price (in dollars per share)	$ 3.20
Range Four [Member]
Exercise price range, lower limit (in dollars per share)	4.45
Exercise price range, upper limit (in dollars per share)	$ 4.80
Options outstanding, number (in shares) | shares	11,900
Options outstanding, weighted average exercise price (in dollars per share)	$ 4.72
Options outstanding, weighted average remaining contractual term (Year)	8 years 2 months 12 days
$0.66Options exercisable, number exercisable (in shares) | shares	5,319
Options exercisable, weighted average exercise price (in dollars per share)	$ 4.71
Range Five [Member]
Exercise price range, lower limit (in dollars per share)	5.10
Exercise price range, upper limit (in dollars per share)	$ 5.40
Options outstanding, number (in shares) | shares	88,000
Options outstanding, weighted average exercise price (in dollars per share)	$ 5.28
Options outstanding, weighted average remaining contractual term (Year)	8 years
$0.66Options exercisable, number exercisable (in shares) | shares	63,250
Options exercisable, weighted average exercise price (in dollars per share)	$ 5.34
Range Six [Member]
Exercise price range, lower limit (in dollars per share)	6.90
Exercise price range, upper limit (in dollars per share)	$ 6.90
Options outstanding, number (in shares) | shares	5,400
Options outstanding, weighted average exercise price (in dollars per share)	$ 6.90
Options outstanding, weighted average remaining contractual term (Year)	7 years 6 months
$0.66Options exercisable, number exercisable (in shares) | shares	3,376
Options exercisable, weighted average exercise price (in dollars per share)	$ 6.90
Range Seven [Member]
Exercise price range, lower limit (in dollars per share)	8.60
Exercise price range, upper limit (in dollars per share)	$ 8.91
Options outstanding, number (in shares) | shares	822,332
Options outstanding, weighted average exercise price (in dollars per share)	$ 8.69
Options outstanding, weighted average remaining contractual term (Year)	7 years 1 month 6 days
$0.66Options exercisable, number exercisable (in shares) | shares	583,220
Options exercisable, weighted average exercise price (in dollars per share)	$ 8.69
Range Eight [Member]
Exercise price range, lower limit (in dollars per share)	10.90
Exercise price range, upper limit (in dollars per share)	$ 13.60
Options outstanding, number (in shares) | shares	15,500
Options outstanding, weighted average exercise price (in dollars per share)	$ 12.64
Options outstanding, weighted average remaining contractual term (Year)	7 years 4 months 24 days
$0.66Options exercisable, number exercisable (in shares) | shares	13,553
Options exercisable, weighted average exercise price (in dollars per share)	$ 12.89
Range Nine [Member]
Exercise price range, lower limit (in dollars per share)	380
Exercise price range, upper limit (in dollars per share)	$ 9,920
Options outstanding, number (in shares) | shares	3,386
Options outstanding, weighted average exercise price (in dollars per share)	$ 2,869.31
Options outstanding, weighted average remaining contractual term (Year)	5 years 6 months
$0.66Options exercisable, number exercisable (in shares) | shares	3,383
Options exercisable, weighted average exercise price (in dollars per share)	$ 2,870.91

Note 12 - Summary of Stock Op_6

Note 12 - Summary of Stock Options - Valuation Assumptions for Stock Options (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Expected term (Year)	6 years	5 years	6 years	6 years
Average volatility	89%	84%	88%	76%
Risk-free interest rate	2.69%	0.81%	1.46%	0.97%
Dividend yield	0%	0%	0%	0%

Note 12 - Summary of Stock Op_7

Note 12 - Summary of Stock Options - Stock-based Compensation Expense Included in the Statement of Income (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Stock-based compensation expense	$ 868	$ 1,088	$ 2,737	$ 2,765
Cost of Sales [Member]
Stock-based compensation expense	64	76	193	191
Research and Development Expense [Member]
Stock-based compensation expense	118	131	361	330
Selling, General and Administrative Expenses [Member]
Stock-based compensation expense	$ 686	$ 881	$ 2,183	$ 2,244

Note 13 - Income Taxes (Details

Note 13 - Income Taxes (Details Textual) - USD ($) Pure in Thousands, $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2022
Income Tax Expense (Benefit), Total			$ 0
Unrecognized Tax Benefits, Ending Balance	$ 0		$ 0
Effective Income Tax Rate Reconciliation, Percent, Total	0%	0%	0%	0%
Forecast [Member]
Effective Income Tax Rate Reconciliation, Percent, Total					0%

Note 14 - Related Party Trans_2

Note 14 - Related Party Transactions (Details Textual) - Stellartech Research Corporation [Member]		3 Months Ended		9 Months Ended		160 Months Ended
	Jun. 01, 2006	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($) shares	Sep. 30, 2021 USD ($)	Sep. 30, 2019	Dec. 31, 2021 USD ($)
Stock Issued During Period, Shares, New Issues (in shares) | shares				38
Related Party Transaction, Amounts of Transaction		$ 0	$ 50,000	$ 0	$ 203,000
Due to Related Parties, Total		$ 0		$ 0			$ 0
Electricity, Generation [Member]
Development and Manufacturing Agreement, Number of Units	300
Development and Manufacturing Agreement, Number of Units Purchased						855